Drugs / ALLO-ASC-SHEET
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05157958 | May 2023 → Oct 2025 | epidermolysis bullosa dystrophica | Anterogen Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04497805 | Sep 2020 → Dec 2024 | ulcer of lower limbs | Anterogen Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-04-03 | Anterogen Co., Ltd. | Regulatory [보도자료] 안트로젠 ‘알로스템’, 日 후생성 품목허가 획득 anterogen.com ↗ |
| 2026-01-15 | Anterogen Co., Ltd. | Regulatory PMDA 리뷰 진행중 anterogen.com ↗
PMDA는 알로스템(ALLO-ASC-SHEET)의 허가 리뷰를 진행하고 있으며 PMDA는 절차적 측면에서의 검증에 매우 신중한 기관입니다. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-03 | Anterogen Co., Ltd. | [보도자료] 안트로젠 ‘알로스템’, 日 후생성 품목허가 획득 anterogen.com ↗ |
| 2026-01-15 | Anterogen Co., Ltd. | PMDA 리뷰 진행중 anterogen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALLO-ASC-SHEET | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04497805 ↗ |
| Modality | Cell therapy | “Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells” NCT04497805 ↗ |